Longitudinal changes in Spirometry in perinatally HIV-infected South African adolescents on antiretroviral therapy.
Despite increased access to highly active antiretroviral therapy (HAART), lung disease remains common in HIV-infected adolescents. There is limited information on changes in lung function over time in perinatally HIV-infected adolescents on HAART. To investigate the progression of spirometry findings over 2 years in HIV-infected adolescents on HAART in a prospective cohort, the Cape Town Adolescent Anti-retroviral cohort (CTAAC). HIV-infected adolescents aged 9-14 years, with at least 6 months of HAART, and a comparator group of healthy HIV-uninfected, age-matched controls were enrolled in CTAAC. Spirometry and bronchodilator testing was done at baseline, 12 and 24 months. Mixed-effect models were used to compute longitudinal changes in lung function. Five hundred and fifteen HIV-infected adolescents, mean (SD) age, 12 (1.6) years, 50.4% male; and 110 HIV-uninfected adolescents, mean (SD) age 11.8 (1.8), 45.6% male, were tested at baseline, 477 (93%) HIV-infected and 102 (93%) HIV-uninfected at 12 months and 473 (92%) HIV-infected and 97 (88%) uninfected adolescents at 24 months. Only 5.4% of the HIV-infected adolescents had HIV viral load>10000 copies/ml at baseline. FEV1 and FVC were lower in the HIV-infected compared to the uninfected adolescents and tracked with no deterioration or catch up over 2 years. Previous pulmonary tuberculosis (PTB) or lower respiratory tract infection (LRTI) was significantly associated with reduced FEV1 and FVC, p<0.05 for both. HIV-infected adolescents had lower lung function over 2 years than HIV-uninfected. This study highlights the need for lung function surveillance and prevention of LRTIs and PTB in HIV-infected adolescents.